EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Histone Deacetylases in Retinoblastoma

Malwina Lisek iD, Julia Tomczak iD, Julia Swiatek, Aleksandra Kaluza, Tomasz Boczek iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25136910 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Malwina Lisek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neurochemistry, Medical University of Lodz, 90-419 Lodz, Poland. Hauptthemen laut MEDLINE: Retinoblastoma, Histone Deacetylases, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki (Poland).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoblastoma, a pediatric ocular malignancy, presents significant challenges in comprehending its molecular underpinnings and targeted therapeutic approaches. The dysregulated activity of histone deacetylases (HDACs) has been associated with retinoblastoma pathogenesis, influencing critical cellular processes like cell cycle regulation or retinal ganglion cell apoptosis. Through their deacetylase activity, HDACs exert control over key tumor suppressors and oncogenes, influencing the delicate equilibrium between proliferation and cell death. Furthermore, the interplay between HDACs and the retinoblastoma protein pathway, a pivotal aspect of retinoblastoma etiology, reveals a complex network of interactions influencing the tumor microenvironment. The examination of HDAC inhibitors, encompassing both established and novel compounds, offers insights into potential approaches to restore acetylation balance and impede retinoblastoma progression. Moreover, the identification of specific HDAC isoforms exhibiting varying expression in retinoblastoma provides avenues for personalized therapeutic strategies, allowing for interventions tailored to individual patient profiles. This review focuses on the intricate interrelationship between HDACs and retinoblastoma, shedding light on epigenetic mechanisms that control tumor development and progression. The exploration of HDAC-targeted therapies underscores the potential for innovative treatment modalities in the pursuit of more efficacious and personalized management strategies for this disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RetinoblastomaHistone DeacetylasesHistone Deacetylase InhibitorsHumansAnimalsRetinal NeoplasmsEpigenesis, GeneticAcetylationTumor MicroenvironmentGene Expression Regulation, NeoplasticRetinoblastoma Protein

Stichwörter der Autor:innen

cancer treatment therapieschromatic remodelinggene expressionhistone deacetylase inhibitorsretinoblastoma

Substanzen

Histone DeacetylasesHistone Deacetylase InhibitorsRetinoblastoma Protein

Autor:innen und Institutionen

  • Department of Molecular Neurochemistry, Medical University of Lodz, 90-419 Lodz, Poland.

ORCID-Profile: Malwina Lisek, Julia Tomczak, Tomasz Boczek

Förderung

  • Narodowe Centrum Nauki (Poland)

Zitieren

APA

Lisek, M., Tomczak, J., Swiatek, J., Kaluza, A., & Boczek, T. (2024). Histone Deacetylases in Retinoblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25136910

Vancouver

Lisek M, Tomczak J, Swiatek J, Kaluza A, Boczek T. Histone Deacetylases in Retinoblastoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25136910

BibTeX
@article{Lisek2024,
  author = {Lisek, Malwina and Tomczak, Julia and Swiatek, Julia and Kaluza, Aleksandra and Boczek, Tomasz},
  title = {Histone Deacetylases in Retinoblastoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25136910}
}
Kostenlos starten →